Concepedia

Publication | Open Access

Cost‐effectiveness analysis of oxaliplatin compared with 5‐fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US

DOIFull Paper Access

68

Citations

21

References

2007

Year

Samuel Aballéa, J Chancellor, Maria Raikou, Michael Drummond, Milton C. Weinstein, Sophia Jourdan, John Bridgewater
Cancer

Abstract

FOLFOX4 is likely to be cost-effective compared with 5-FU/LV in the adjuvant treatment of stage III colon cancer. The incremental cost-effectiveness ratio compares favorably with other funded interventions in oncology.

References

YearCitations

Page 1